Moleculin Biotech Inc. Common Stock (MBRX)
Stock · NASDAQ · Health Care
$0.2808as of 10/16/2026
Price chart
Active signals
High Beta52.2%
200 SMA Touch0.0%Resistance level
$2.33
Industry
Biotechnology: Pharmaceutical Preparations
MBRX Signal Track Record
How signals performed across all stocks →What MBRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 25 | -13.3% | 44% | September 21, 2026 |
| Volume Spike | 16 | -25.6% | 25% | September 25, 2026 |
| Bollinger Band Breakout | 16 | -17.1% | 25% | September 9, 2026 |
| Any 20-session window (baseline) | -7.0% | 37% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MBRX
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 17
- Website
- moleculin.com/
Fundamentals
- 1-day range
- $0.3701$0.426
- Market cap
- $7.50M
- P/E (trailing)
- —
- P/E (forward)
- -0.00
- EPS (trailing)
- $-14.53
- Dividend yield
- —
- Beta
- 2.11
- Avg. volume
- 1.31M
- Dividend pay date
- February 1, 2021
52-week range
$0.1614$15.75
Forecasts
3 analyst ratings
Buy 89%
Hold 11%
Sell 0%
1-year price forecast
High
$31
+10939.9%
Median
$3
+968.4%
Low
$2
+612.3%
Moleculin Biotech Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MBRXMoleculin Biotech Inc. Common Stock$0.28▼ 24.32%Market cap $7.50MP/E —$0.1614$15.75
- MTVAMetaVia Inc. Common Stock$1.26▼ 8.03%Market cap $7.49MP/E —$0.9661$14.85
- BOLTBolt Biotherapeutics Inc. Common Stock$4▼ 5.66%Market cap $7.44MP/E —$3.1$7.2
- CANFCan-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares$1.76▼ 4.86%Market cap $7.63MP/E —$299$9,000,000
- CNSPCNS Pharmaceuticals Inc. Common Stock$4.85▼ 6.30%Market cap $7.65MP/E —$1.9$10.54
- PCSAProcessa Pharmaceuticals Inc. Common Stock$1.69▲ 0.60%Market cap $7.65MP/E 3.31$1.04$11
- ADXNAddex Therapeutics Ltd American Depositary Shares$2.76▼ 8.61%Market cap $7.34MP/E —$0.018$0.069
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MBRX Moleculin Biotech Inc. Common Stock | $7.50M | — | $0.28 | ▼ 24.32% | $0.1614$15.75 |
| MTVA MetaVia Inc. Common Stock | $7.49M | — | $1.26 | ▼ 8.03% | $0.9661$14.85 |
| BOLT Bolt Biotherapeutics Inc. Common Stock | $7.44M | — | $4 | ▼ 5.66% | $3.1$7.2 |
| CANF Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares | $7.63M | — | $1.76 | ▼ 4.86% | $299$9,000,000 |
| CNSP CNS Pharmaceuticals Inc. Common Stock | $7.65M | — | $4.85 | ▼ 6.30% | $1.9$10.54 |
| PCSA Processa Pharmaceuticals Inc. Common Stock | $7.65M | 3.31 | $1.69 | ▲ 0.60% | $1.04$11 |
| ADXN Addex Therapeutics Ltd American Depositary Shares | $7.34M | — | $2.76 | ▼ 8.61% | $0.018$0.069 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Moleculin Biotech Announces 1-For-20 Reverse Stock Split, Effective October 20benzinga · 10/16/2026
- Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth SummitYahoo · 10/7/2026
- Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data ReadoutYahoo · 9/29/2026
- Moleculin Biotech Completes Patient Enrollment In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Adults With Relapsed Or Refractory Acute Myeloid LeukemiaBenzinga · 9/29/2026
- Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular MedicineYahoo · 9/28/2026
- Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACRYahoo · 9/25/2026
- Moleculin Biotech Announces Preclinical Data Showing Annamycin Antitumor Activity In Pancreatic Cancer Is Immune-MediatedBenzinga · 9/25/2026
- Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040Yahoo · 9/23/2026
- Let's take a look at the stocks that are in motion in today's session.ChartMill · 9/21/2026
Insider Activity
Insider Actions →Acquired
4.00M
Disposed
187
- KLEMP WALTER V · August 3, 2026 · Grant1.60M
- KLEMP WALTER V · August 3, 2026 · Buy533.3K
- Foster Jonathan P. · August 3, 2026 · Buy880.0K
- Foster Jonathan P. · August 3, 2026 · Buy293.3K
- PICKER DONALD H · August 3, 2026 · Buy520.0K
- PICKER DONALD H · August 3, 2026 · Buy173.3K
- KLEMP WALTER V · June 22, 2026 · Option Exercise360
- KLEMP WALTER V · June 22, 2026 · Tax Withholding88 @ $3.12
- Foster Jonathan P. · June 22, 2026 · Option Exercise174
- Foster Jonathan P. · June 22, 2026 · Tax Withholding41 @ $3.12
- PICKER DONALD H · June 22, 2026 · Option Exercise71
- PICKER DONALD H · June 22, 2026 · Tax Withholding21 @ $3.12
- KLEMP WALTER V · June 20, 2026 · Option Exercise150
- KLEMP WALTER V · June 20, 2026 · Tax Withholding37 @ $2.88
- Foster Jonathan P. · June 20, 2026 · Option Exercise109
Institutional Ownership
March 31, 2026
- Total shares held
- 146.0K
- Total value held
- $303.0K
- Institutional holders
- 18
Top holders this quarter
- Unknown75.0K
- Unknown32.3K
- Unknown13.9K
- Unknown13.7K
- Unknown4.4K
- Unknown3.4K
- Unknown1.8K
- Unknown491
- Unknown434
- Unknown281
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
MBRX Completes Phase 2/3 AML Trial Enrollment, Publishes Cardiac Safety
Moleculin Biotech finished enrolling patients in Part A of its Phase 2/3 MIRACLE study for Annamycin plus cytarabine, keeping the program on schedule for a Q1 2027 data readout. The company also released a peer‑reviewed cardiac safety analysis of Annamycin and presented preclinical data showing the drug can turn cold pancreatic tumors hot through immune‑mediated mechanisms. These updates reinforce the company’s progress in both AML and solid‑tumor indications.
MBRX Completes Phase 2/3 AML Trial Enrollment, Publishes Cardiac Safety. Moleculin Biotech finished enrolling patients in Part A of its Phase 2/3 MIRACLE study for Annamycin plus cytarabine, keeping the program on schedule for a Q1 2027 data readout. The company also released a peer‑reviewed cardiac safety analysis of Annamycin and presented preclinical data showing the drug can turn cold pancreatic tumors hot through immune‑mediated mechanisms. These updates reinforce the company’s progress in both AML and solid‑tumor indications.